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Abstract
Background: Artemisinin combination therapy (ACT) is first-line treatment for malaria in most endemic countries
and is increasingly available in the private sector. Most studies on ACT adherence have been conducted in the
public sector, with minimal data from private retailers.
Methods: Parallel studies were conducted in Tanzania, in which patients obtaining artemether-lumefantrine (AL)
at 40 randomly selected public health facilities and 37 accredited drug dispensing outlets (ADDOs) were visited at
home and questioned about doses taken. The effect of sector on adherence, controlling for potential confounders
was assessed using logistic regression with a random effect for outlet.
Results: Of 572 health facility patients and 450 ADDO patients, 74.5% (95% CI: 69.8, 78.8) and 69.8% (95% CI: 64.6,
74.5), respectively, completed treatment and 46.0% (95% CI: 40.9, 51.2) and 34.8% (95% CI: 30.1, 39.8) took each
dose at the correct time (‘timely completion’). ADDO patients were wealthier, more educated, older, sought care
later in the day, and were less likely to test positive for malaria than health facility patients. Controlling for patient
characteristics, the adjusted odds of completed treatment and of timely completion for ADDO patients were 0.65
(95% CI: 0.43, 1.00) and 0.69 (95% CI: 0.47, 1.01) times that of health facility patients. Higher socio-economic status
was associated with both adherence measures. Higher education was associated with completed treatment
(adjusted OR = 1.68, 95% CI: 1.20, 2.36); obtaining AL in the evening was associated with timely completion
(adjusted OR = 0.35, 95% CI: 0.19, 0.64). Factors associated with adherence in each sector were examined separately.
In both sectors, recalling correct instructions was positively associated with both adherence measures. In health
facility patients, but not ADDO patients, taking the first dose of AL at the outlet was associated with timely
completion (adjusted OR = 2.11, 95% CI: 1.46, 3.04).
Conclusion: When controlling for patient characteristics, there was some evidence that the adjusted odds of
adherence for ADDO patients was lower than that for public health facility patients. Better understanding is needed
of which patient care aspects are most important for adherence, including the role of effective provision of advice.
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Background
As artemisinin-based combination therapy (ACT) for
malaria becomes widely available, patient adherence to
the full course of treatment is increasingly important to
ensure positive clinical outcomes and minimize the
selection of drug-resistant parasites [1-3]. ACT is the
first-line treatment for Plasmodium falciparum malaria
in most malaria-endemic countries and has become in-
creasingly available in the private retail sector, where
many patients seek care for malaria [4-9].
Estimates of patient adherence to ACT range from 39
to 100%, reflecting both variation in patient characteris-
tics, interaction with providers, study settings, differences
in study procedures, and methods of assessing adherence
[10,11]. The vast majority of studies designed to measure
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adherence have been conducted in the public sector, while
a few studies have used household survey data to assess
adherence from mixed community sources [12-17]. Only
one study had specifically addressed patient adherence to
ACT obtained in the private sector. This study, conducted
in a convenience sample of four shops in a single Ugandan
district where subsidized ACT had been made available
through a pilot programme, reported that 66% of patients
seeking treatment completed the full course of ACT [18].
As access to ACT increases, there is a need to under-
stand levels and determinants of patient adherence in both
public and private sectors, in order to design and target ap-
propriate interventions. Patients seeking care in the private
retail sector may have different characteristics (e.g., age,
socio-economic status, illness severity, etc.) than patients
who seek care in public health facilities [7,19,20], though
some patients seek care in both sectors. Similarly, provider
characteristics (e.g., training, communication, reputation,
costs, drug availability, motivation, etc.) may also vary and
affect where patients seek care [7,21]. It is unclear how
these differences affect patient adherence.
In Tanzania, artemether-lumefantrine (AL) for treat-
ment of uncomplicated malaria was first rolled out to
public health facilities in 2006. The recommended treat-
ment regimen is six doses of AL over three days, with one
to four tablets (20 mg artemether/120 mg lumefantrine)
per dose depending on the patient's weight/age band.
National guidelines state that the first dose should be
taken under observation of the dispenser, the second dose
eight hours after the first dose, and the remaining doses
morning and evening of the second and third days [22].
Treatment at public health facilities for children under five
years of age and pregnant women is intended to be free of
charge, but this policy is not always followed [20].
Treatment for malaria in the private sector in Tanzania
is sought at private health facilities, pharmacies, drug
shops, and general stores. More than two-thirds of anti-
malarial drug sales from private for-profit providers occur
in drug shops [23], many of which have been upgraded
through the accredited drug dispensing outlet (ADDO)
programme. ADDOs were first piloted in 2003 in order to
improve availability, quality, and affordability of pharma-
ceutical services in rural and peri-urban areas without
pharmacies. ADDOs have now been rolled-out nation-
wide, with an estimated 9,000 ADDOs serving the 25 re-
gions of mainland Tanzania [24]. The ADDO programme
involves multiple components including training, ac-
creditation, and regulatory oversight by trained inspec-
tors [24-26]. Dispensers are required to have a health
qualification of a nurse assistant or higher and must at-
tend a six-week training course on topics such as business
practices, regulations, record-keeping, use of ADDO-
approved medicines, dispenser ethics and communica-
tion skills. ADDOs are allowed to sell a limited number
of prescription-only drugs, including an approved list of
antibiotics and anti-malarial drugs. Availability of ACT
was limited in ADDOs until the implementation of the
Affordable Medicines Facility- malaria (AMFm) in 2010,
which led to a significant reduction in price and a corre-
sponding increase in availability [23,27].
This paper reports results of two parallel, contempor-
aneous studies in southern Tanzania to compare patient
adherence to ACT obtained in public health facilities with
adherence to ACT obtained from ADDOs in the same
area and to examine factors associated with adherence in
each sector.
Methods
Study setting
The studies were conducted in Mtwara, a rural region in
southeastern Tanzania with more than a third of the
population in the lowest national wealth quintile [28]. In
2012, malaria prevalence in Mtwara in patients of all ages
seeking care for febrile illness was 15% among patients
attending ADDOs and 32% among patients attending
public health facilities [29,30]. Conversion of drug shops
to ADDOs in Mtwara commenced in 2006, with all drug
shops in Mtwara officially required to have upgraded to
ADDO status by 2011. At the time of the study, some
shops had not yet paid fees, received training, or been
visited by inspectors but were tolerated as ‘prospective
ADDOs’ (in this paper the term ADDOs is used to include
both accredited outlets and ‘prospective ADDOs’). To
support the increased availability of ACT in ADDOs, the
government offered a one-day training that included treat-
ment of malaria with ACT to dispensers with previous
nursing training in Mtwara in August 2011.
Study design
In health facilities, a descriptive study was conducted to
assess patient adherence to AL. The study in ADDOs was
designed as part of a cluster-randomized trial to evaluate a
text message intervention to improve dispenser know-
ledge of advice to provide to patients obtaining AL. Details
of the intervention and results of the trial are presented
separately [31]. Only data from the control arm, which did
not receive any intervention, are presented here.
Sample size calculations
The target sample size for ADDO patients was based on
the text message intervention trial [31], and a similar
sample size was desired for public health facilities within
the constraints of study resources. Based on adherence
previously reported among patients obtaining ACT at pub-
lic health facilities in Tanzania, which ranged from 75 to
98% [32-34], adherence among patients attending public
health facilities was expected to be 75%, with lower adher-
ence among patients attending ADDOs (60%). Assuming a
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hypothesized design effect of 2.5 and 20% loss to follow-
up, 448 registered patients from 36 outlets in each sector
(approximately 12 to 13 patients per outlet) would have
80% power to detect this difference with 95% confidence.
Given the lower design effect observed in the study (1.5)
and more interviewed patients than anticipated, the study
was powered to detect a 10 percentage point difference
between sectors, but was not able to detect if a smaller
difference in completion rates between sectors was due
to random error.
Selection of outlets
A list of all public dispensaries and health centres in
Mtwara, excluding district hospitals, was compiled by vis-
iting each district and interviewing the district medical of-
ficers. The health facilities were randomly ordered, and
the first 40 health facilities were selected. Sampling of
ADDOs was based on a census in Mtwara of all ADDOs,
including prospective ADDOs, conducted prior to the text
message intervention trial. From this list, ADDOs were
selected sequentially at random, with all ADDOs within
400 m of a selected ADDO, or any ADDO where staff
from a selected ADDO also worked, removed from the
sampling frame. Forty ADDOs were randomized to the
control arm [31].
Study procedures
From September through November 2012, dispensers at
selected public health facilities and ADDOs were visited
by study supervisors and given a standard introduction
about study objectives. In order to limit patients’ aware-
ness of the primary interest in adherence, which could
have led to a biased assessment, dispensers were told the
focus was how patients chose to treat fever and that
some, but not all, patients would be visited at their homes.
Dispensers were asked to fill out a registration form for all
patients dispensed any treatment for fever, including day
and time of the visit, the patient’s name, drugs dispensed,
and a description of where the patient lived. Dispensers
were provided with blister packs of AL to be dispensed in
public health facilities to patients prescribed ACT, and in
ADDOs to patients indicating an intention to purchase
treatment for malaria. Study staff visited outlets every day
to check and collect registration forms. While the intention
had been to register 12 patients obtaining ACT for one
week per outlet, the protocol was adjusted due to low at-
tendance at some outlets to register all patients obtaining
ACT for two to three weeks per outlet.
Eligible patients who obtained AL were identified
from the registration forms and assigned patient identi-
fication numbers. Patients were visited at their homes
three days later (day 4), and all attempts to locate and
interview patients were recorded. Where written in-
formed consent was given, patients or their caregivers
were asked about demographic and socio-economic
characteristics, treatment-seeking history, symptoms,
and detailed information about each dose of AL taken.
Patients were asked if dispensers provided each of sev-
eral aspects of advice on AL (e.g., number of pills to
take per dose, when to take second dose, etc.), and if so,
what advice was given. Blister packs were also requested
for a pill count. Since the P. falciparum histidine-rich
protein II (HRP-2) persists in the blood following treat-
ment, HRP-2-based malaria rapid diagnostic tests (mRDTs)
(Pf-specific from ICT Diagnostics, Cape Town, South
Africa) were conducted to indicate infection prior to
treatment. Blood smears were collected to detect infec-
tion at the time of interview. Blood smears were stained
in the field and transported to the Ifakara Health Institute,
where they were double-read by two microscopists blinded
to results from each other and the mRDT, with discrepant
readings resolved by a third microscopist.
Adherence was defined in two ways [10]. Patients were
considered to have verified completed treatment if they
reported taking all doses by the time of the interview
and, when available, a pill count verified that no pills
remained in the blister pack. Where blister packs were
not available, self-report alone determined if patients com-
pleted treatment. The second, more stringent definition
included a time component, based on patient reports of
the time each dose was taken using the Swahili times of
day: alfajiri (early morning), asubuhi (morning), mchana
(afternoon), jioni (evening), usiku (night), and usiku sana
(late night). Patients were considered to have verified
timely completion if they took the correct number of pills
for each dose, and took the second dose at the Swahili
time of day corresponding with eight hours after the first
dose, followed by taking each of the remaining doses at
the Swahili time of day corresponding with 12 hours after
the previous dose, verified when possible by the absence
of pills in the blister pack. The terms completed treat-
ment and timely completion are hereafter used to refer
to these definitions.
Data entry and analysis
All patient and dispenser interview data were collected
using personal digital assistants, and data extracted from
study forms (census, registration and follow-up forms)
were double entered into Microsoft Access databases. Data
were analysed in Stata 11.0 (Stata Corporation, College
Station, USA). Robust standard errors were used for
percentages and 95% confidence intervals, with p-values
reported for the Pearson design-based F test. Wealth quin-
tiles describing socio-economic status were assigned to
patients based on standard Demographic and Health Sur-
vey variables, using principal components analysis of the
pooled sample of public health facility and ADDO patients
[28]. Two analyses of factors associated with adherence
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were conducted: (i) a comparison of adherence between
the public and private sectors controlling for patient char-
acteristics; and, (ii) an analysis within each sector explor-
ing the association of adherence with factors related to the
care received at the outlet and patient characteristics.
Comparison of adherence between sectors
In the analysis on the impact of sector on patient adher-
ence, random effects logistic regression was used for both
completed treatment and timely completion to compare
the odds of adherence between private sector ADDO pa-
tients and public sector health facility patients, adjusting
for patient characteristics identified a priori (age group,
education and time between obtaining AL and interview)
or those that made important changes to the odds ratio
for sector in bivariate models. In this analysis, no adjust-
ment was made for variables related to care received at
the outlet (e.g., taking first dose at outlet, recalling correct
instructions on how to take AL, etc.), as these factors
might mediate the effect of sector (i.e., lie on the causal
pathway between sector and adherence).
Factors associated with adherence within sectors
Within each sector, the association of variables related
to care received at the outlet with 1) completed treatment,
and, 2) timely completion was explored in univariate and
multivariate models. Logistic regression with robust stand-
ard errors was used, as checks showed that the quadrature
approximations for random effects models were not reli-
able. Patient characteristics and care-related variables that
were associated with completed treatment or timely com-
pletion in either sector in unadjusted analyses were in-
cluded in all four multivariate models.
Ethics
All questionnaires, consent forms and other study docu-
ments were translated into Swahili and piloted prior to
use. Written informed consent was collected from dis-
pensers prior to census, patient registration, and interview
and from patients or their caregivers prior to interview.
The study protocol was approved by the ethical review
boards of Ifakara Health Institute and London School of
Hygiene and Tropical Medicine. CDC advisors provided
technical assistance in design and analysis but were not
engaged in data collection and did not have access to per-
sonal identifiers.
Results
Patient characteristics, care received, and status at interview
Data were collected from patients obtaining AL at all 40
selected health facilities and 37 of 40 selected ADDOs,
with three ADDOs closed or refusing to participate. Of
604 registered health facility patients obtaining AL (me-
dian = 16 patients per outlet, range two to 32), 572
patients (95%) were interviewed. From ADDOs, 537
patients obtaining AL were registered (median = 17 pa-
tients per outlet, range one to 29), and 450 patients
(84%) were interviewed. The most common reasons in
both sectors for non-completion of interviews were not
locating the patient’s home (38% at public facilities and
43% at ADDOs), or the patient having travelled out of
the study region (28 and 16%).
Characteristics of patients differed between sectors
(Table 1). ADDO patients were more likely to be male and
older than those attending public health facilities. ADDO
patients/caregivers were wealthier, with 32% in the least
poor wealth quintile compared to 10% of public health fa-
cility patients, and were more likely to have finished pri-
mary school (72 vs 58%, p = 0.007). Over a third of patients
in both sectors had previously sought care for their illness
episode, many of whom had gone to a general store/kiosk
or taken drugs stored at home or from a neighbour. Re-
ported symptoms were similar across outlet type, except
more patients from public health facilities had experienced
respiratory symptoms (14 vs 7.5%, p = 0.007) and more
ADDO patients had experienced body pain (30 vs 15%, p <
0.0001) or fatigue (18 vs 10%, p = 0.003), with few patients
in either sector reporting convulsions or other signs of se-
vere disease. ADDOs were much more likely than public
health facilities to be located in urban areas, but outlets in
both sectors were attended mostly by patients living within
2.5 km (about half-an-hour walk) from the outlet. ADDO
patients were also more likely to have obtained AL later in
the day, reflecting the fact that most public health facilities
in Mtwara close for outpatient services by mid-afternoon,
while ADDOs often stay open through the evening. Be-
cause of this, the day-4 interview was more likely to occur
earlier (between 60–67 hours from the time the drug was
obtained) for ADDO patients than for public health facility
patients (25 vs 6%).
Table 2 compares care received at the outlet and patient
status at interview for each sector. Half of the public
health facility patients reported being tested for malaria,
while 11% reported being tested in ADDOs, where diag-
nostic tests for malaria had not been officially introduced.
Public health facility patients were slightly more likely to
be told a diagnosis (64 vs 54%, p = 0.051) and more likely
to take the first dose of AL immediately at the outlet (41
vs 10%, p < 0.0001), while ADDO patients were more
likely to pay for AL (98 vs 29%, p < 0.0001). Similar per-
centages of patients using outlets in both sectors reported
receiving advice on how to take AL from the dispenser,
with 60% able to recall correct instructions on the number
of pills per dose, number of doses per day, and number of
days to take AL. Approximately 60% of patients in both
sectors reported being told to take the second dose of AL
after eight hours and to take each dose with food or milk.
Public health facility patients were more likely to recall
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Table 1 Patient characteristics by sector (%, 95% CI)
Public health facilities (N = 572
patients from 40 outlets)
Private ADDOs (N = 450
patients from 37 outlets)
p-value
Male 43.2 (39.9, 46.5) 53.1 (46.8, 59.4) 0.007
Age1
Under 3 years 42.5 (37.4, 47.8) 18.2 (14.5, 22.6)
3 years to under 8 years 28.2 (23.5, 33.3) 23.1 (18.8, 28.0)
8 years to under 12 years 6.6 (4.3, 10.0) 9.1 (6.9, 12.0)
12 years and above 22.7 (18.7, 27.3) 49.6 (43.0, 56.2) <0.0001
Patient (or caregiver if patient below age 12) completed
primary school2
58.2 (50.7, 65.4) 71.8 (65.2, 77.6) 0.007
Socio-economic status3
1st quintile (most poor) 27.9 (23.1, 33.2) 10.2 (7.6, 13.5)
2nd quintile 24.5 (20.5, 29.1) 14.2 (10.1, 19.8)
3rd quintile 20.0 (16.5, 23.9) 20.2 (15.4, 26.1)
4th quintile 17.3 (13.1, 22.6) 23.3 (19.5, 27.6)
5th quintile (least poor) 10.3 (7.4, 14.4) 32.1 (23.3, 42.2) <0.0001
Slept under net the night before the interview 73.6 (68.9, 77.8) 71.4 (65.3, 76.9) 0.6
Sought care for this episode prior to attending outlet 36.4 (31.9, 41.2) 37.8 (31.6, 44.4) 0.7
Sought care at outlet within two days of fever onset4 77.5 (73.5, 81.1) 72.0 (67.8, 75.9) 0.051
Symptoms
Fever or headache 94.1 (91.3, 96.0) 91.1 (87.6, 93.7) 0.1
Respiratory 14.0 (10.5, 18.4) 7.5 (5.3, 10.7) 0.007
Stomach upset 53.5 (47.7, 59.2) 48.9 (42.3 55.6) 0.3
Body/joint pain 15.4 (12.2, 19.1) 30.4 (25.2, 36.2) <0.0001
Fatigue 10.1 (7.5, 13.6) 18.0 (14.2, 22.5) 0.003
Convulsions 2.5 (1.6, 3.9) 0.4 (0.1, 1.7) 0.007
Other5 12.4 (9.6, 15.9) 10.0 (7.5, 13.1) 0.2
Attended an outlet in an urban ward 13.1 (5.1, 29.6) 68.4 (48.3, 83.4) <0.0001
Distance of 2.5 km or less from home to outlet
(by GPS coordinates)6
69.4 (62.6, 75.4) 71.4 (58.5, 81.5) 0.8
Time of day drug was obtained
Morning 77.1 (71.9, 81.6) 44.7 (38.2, 51.3)
Afternoon 18.7 (14.6, 23.6) 26.9 (22.2, 32.2)
Evening 4.2 (2.5, 7.0) 28.4 (21.6, 36.4) <0.0001
Time between obtaining AL and interview (hours)7
60-67 5.8 (3.8, 8.6) 24.8 (20.7, 29.3)
68-72 47.0 (41.7, 52.4) 37.4 (33.1, 41.9)
73-84 32.5 (28.5, 36.7) 21.6 (16.9, 27.2)
85 or more 14.7 (11.4, 18.8) 16.2 (12.1, 21.4) <0.0001
1Age categories based on recommended age breakdown for AL blister packs in Tanzania.
2Caregiver education missing for five public health facility patients.
3Wealth quintiles pooled for public health facilities and ADDOs using principal component analysis of sampled patients based on standard Demographic and
Health Survey variables. Data missing for one public health facility patient.
4Number of days since illness onset missing for 3 public health facility patients and 11 ADDO patients.
5Includes dizziness, crying/fussiness, startling (kustukastuka), sleep-talking (kuweweseka), worms, fast heart rate, stays in sun, red/inflamed eyes, and sores/ulcers.
6GPS data missing from 30 public health facility patients and 52 ADDO patients.
7Rounded to nearest hour. Data missing for 15 public health facility patients and 6 ADDO patients.
Bruxvoort et al. Malaria Journal  (2015) 14:87 Page 5 of 12
being told to finish all doses even if feeling better (78 vs
63%, p = 0.0006). However, less than 5% of patients treated
in either sector reported being advised on possible side ef-
fects or on what to do in case of vomiting within half-an-
hour of taking a dose.
At the time of interview, approximately 14% of both
public health facility and ADDO patients reported a
current fever and 92% could play or work. More pa-
tients who had attended public health facilities tested
positive by the mRDT performed by study staff during
the interview (50% compared to 28% of ADDO patients,
p = 0.001). However, by reference blood smear, indicat-
ing current infection status at the time of interview,
only 2.9% of public health facility patients and 1.4% of
ADDO patients were positive (p = 0.1).
Comparison of adherence between sectors
Among public health facility patients, 74.5% (95% CI: 69.8,
78.8) completed treatment, compared with 69.8% (95% CI:
64.6, 74.5) among ADDO patients (p = 0.2). Timely com-
pletion was much lower and differed between sectors,
with 46.0% (95% CI: 40.9, 51.2) of public health facility pa-
tients and 34.8% (95% CI: 30.1, 39.8) of ADDO patients
taking the correct number of pills at the correct time of
day for each dose (p = 0.003). Variables that made import-
ant differences to the odds ratio for sector in the bivariate
models were wealth quintile, distance from home to out-
let, and time of day AL was obtained, and these were in-
cluded along with age group, patient/caregiver education,
and time between obtaining AL and interview in the
models comparing adherence between sectors. Patients in
Table 2 Care received at outlet and patient status at interview by sector (%, 95% CI)
Public health facilities (N = 572
patients from 40 outlets)
Private ADDOs (N = 450
patients from 37 outlets)
p-value
Treatment received at outlet
Tested for malaria 54.4 (40.3, 67.9) 11.1 (8.0, 15.4) <0.0001
Told diagnosis 64.1 (56.3, 71.1) 53.5 (46.1, 60.8) 0.051
Obtained correct blister pack for age1 78.9 (74.7, 82.5) 83.1 (78.7, 86.8) 0.1
Paid for AL 28.7 (24.0, 34.0) 97.8 (96.1, 98.7) <0.0001
Took first dose of AL at outlet 40.7 (29.8, 52.7) 9.6 (6.3, 14.2) <0.0001
Recall of instructions received from dispenser
Recalled correct instructions given by dispenser on the number
of pills per dose, number of doses, and number of days to take AL
60.8 (56.4, 65.2) 59.3 (53.7, 64.7) 0.7
Recalled that dispenser used packaging as a visual aid to explain
how to take AL
85.6 (81.9, 88.6) 82.9 (77.9, 86.9) 0.3
Reported being told to take the second dose of AL eight hours
after the first dose
58.0 (51.3, 64.5) 63.3 (57.9, 68.4) 0.2
Reported being told to take AL with food or milk 63.8 (57.9, 69.3) 61.8 (54.6, 68.5) 0.7
Reported being told to complete all doses of AL even if feeling better 77.9 (73.5, 81.7) 63.3 (55.7, 70.4) 0.0006
Reported being told to take a replacement dose in case of vomiting
within half hour of taking a dose
1.9 (1.1, 3.5) 2.4 (1.3, 4.6) 0.6
Reported being told about possible side effects 2.3 (1.3, 4.0) 3.0 (1.6, 5.6) 0.6
Health status at interview
Reported current fever at time of interview 13.7 (10.5, 17.7) 14.7 (11.1, 19.1) 0.7
Could play or work at time of interview 92.6 (89.2, 95.1) 92.4 (89.7, 94.5) 0.9
Tested positive by mRDT at interview2 49.6 (39.7, 59.5) 27.9 (20.7, 36.6) 0.001
Tested positive by blood smear collected at interview3 2.9 (1.7, 4.7) 1.4 (0.6, 3.0) 0.1
Adherence to AL
Adherent by ‘verified completed treatment’4 74.6 (69.8, 78.8) 69.8 (64.6, 74.5) 0.2
Adherent by ‘verified timely completion’5 46.0 (40.9, 51.2) 34.8 (30.1, 39.8) 0.003
1Age categories based on recommended age breakdown for AL blister packs in Tanzania.
2mRDT data missing for 7 public health facility patients and 17 ADDO patients.
3Blood smear data missing for 15 public health facility patients and 18 ADDO patients.
4Patient completed all doses, verified by pill count when available. Data missing for 2 public health facility patients and 3 ADDO patients.
5Patient completed each dose at correct time with the correct number of pills per dose, verified by pill count when available. Data missing for 13 public health
facility patients and 10 ADDO patients.
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the two least poor wealth quintiles had higher adjusted
odds of both measures of adherence compared to those in
the poorest wealth quintile (Table 3). The adjusted odds of
completed treatment for those who had finished primary
school was 1.68 times that of patients who had not (95%
CI: 1.20, 2.36; p = 0.003), but there was no evidence of an
association with timely completion (aOR = 1.06, 95% CI:
0.77, 1.75; p = 0.9). Compared to patients who obtained
AL in the morning, patients who obtained AL in the even-
ing were similarly likely to complete treatment (aOR =
0.93, 95% CI: 0.50, 1.70; p = 0.8), but had much lower
adjusted odds of timely completion (aOR = 0.35, 95% CI:
0.19, 0.64; p = 0.001). Furthermore, patients interviewed
a longer time after obtaining AL (68–72 hours, 73–84
hours, and 85 hours or more) had higher adjusted odds
of completed treatment and timely completion than pa-
tients visited 60–67 hours after obtaining AL (Table 3).
When controlling for these patient characteristics, the
adjusted odds of completed treatment for ADDO pa-
tients was 0.65 times the odds of completed treatment
for public health facility patients (95% CI: 0.43, 1.00;
p = 0.048), and the adjusted odds of timely completion
for ADDO patients was 0.69 that of health facility pa-
tients (95% CI: 0.47, 1.01; p = 0.056).
Factors associated with adherence within sectors
Unadjusted associations of patient characteristics and care
received at the outlet with completed treatment and timely
completion are presented for each sector in Additional
files 1 and 2. Variables not associated with either adher-
ence measure in either sector, such as patient sex,
having sought previous treatment, report of specific symp-
toms, and paying for AL, were not included in the sector
specific multivariate analyses shown in Table 4. In contrast
with the analyses comparing the effect of sector on adher-
ence, in these sector specific models there were no clear
Table 3 Effect of sector on adherence controlling for potential confounders1
Verified completed treatment2 Verified timely completion3
Adjusted odds ratio p-value Adjusted odds ratio p-value
Attended ADDO vs. public health facility 0.65 (0.43, 1.00) 0.048 0.69 (0.47, 1.01) 0.056
Age4
Under 3 years (ref) --- --- --- ---
3 years to under 8 years 1.01 (0.67, 1.52) 0.9 0.88 (0.61, 1.28) 0.5
8 years to under 12 years 1.07 (0.57, 2.09) 0.8 1.12 (0.62, 2.01) 0.7
12 years and above 1.02 (0.56, 2.05) 0.8 0.87 (0.60, 1.27) 0.5
Patient (or caregiver if patient below age 12) completed primary school 1.68 (1.20, 2.36) 0.003 1.06 (0.77, 1.45) 0.9
Socio-economic status5
1st quintile (most poor, ref) --- ---
2nd quintile 0.98 (0.62, 1.57) 0.9 1.04 (0.66, 1.64) 0.9
3rd quintile 1.17 (0.73, 1.88) 0.5 1.10 (0.70, 1.75) 0.7
4th quintile 2.25 (1.33, 3.81) 0.003 1.64 (1.03, 2.65) 0.039
5th quintile (least poor) 2.24 (1.28, 3.81) 0.005 2.34 (1.40, 3.93) 0.001
Distance from home to outlet within 2.5 km by GPS 1.30 (0.92, 1.85) 0.2 1.20 (0.87, 1.66) 0.3
Time of day drug was obtained
Morning (ref) --- --- --- ---
Afternoon 0.96 (0.62, 1.47) 0.8 0.70 (0.48, 1.03) 0.070
Evening 0.93 (0.50, 1.70) 0.8 0.35 (0.19, 0.64) 0.001
Time between obtaining AL and interview (hours)
60-67 (ref) --- --- --- ---
68-72 2.43 (1.39, 4.23) 0.002 1.46 (0.81, 2.63) 0.2
73-84 2.83 (1.49, 5.37) 0.001 1.92 (1.00, 3.66) 0.049
85 or more 6.44 (3.19, 13.01) <0.001 2.61(1.37, 4.95) 0.003
1Number of observations = 912 (110 patients excluded from model due to missing data) and number of outlets = 77. Covariates are those presented in Table.
2Patient completed all doses, verified by pill count when available. Data missing for 5 patients.
3For each dose, patients took the correct number of pills at the correct time of day, verified by pill count when available. Data missing for 23 patients.
4Age categories based on recommended age breakdown for AL blister packs in Tanzania.
5Wealth quintiles pooled for public health facilities and ADDOs using principal component analysis of sampled patients based on standard Demographic and
Health Survey variables.
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Table 4 Multivariate analyses of factors associated with adherence, by sector
Verified completed treatment1 Verified timely completion2
Public health facilities
(N = 572)3
ADDOs (N = 450)4 Public health facilities
(N = 572)3
ADDOs (N = 450)4
Adjusted odds
ratio (95% CI)
p-value Adjusted odds
ratio (95% CI)
p value Adjusted odds
ratio (95% CI)
p-value Adjusted odds
ratio (95% CI)
p-value
Age5
Under 3 years (ref) --- --- --- --- --- --- --- ---
3 years to under 8 years 1.32 (0.76, 2.28) 0.3 0.69 (0.35, 1.36) 0.3 1.03 (0.60, 1.78) 0.9 0.51 (0.28, 0.93) 0.029
8 years to under 12 years 1.33 (0.49, 3.57) 0.6 0.97 (0.43, 2.16) 0.9 2.25 (0.74, 6.86) 0.2 0.75 (0.31, 1.82) 0.5
12 years and above 1.19 (0.62, 2.31) 0.6 0.94 (0.48, 1.84) 0.9 1.06 (0.59, 1.93) 0.8 0.69 (0.35, 1.38) 0.3
Patient (or caregiver if patient
below age 12) completed
primary school
1.16 (0.70, 1.91) 0.6 1.56 (1.00, 2.43) 0.050 0.88 (0.55, 1.40) 0.6 0.94 (0.54, 1.63) 0.8
Socio-economic status6
1st quintile (most poor, ref) --- --- --- --- --- --- --- ---
2nd quintile 0.97 (0.60, 1.57) 0.9 0.82 (0.38, 1.81) 0.6 0.93 (0.52, 1.64) 0.8 1.19 (0.62, 2.26) 0.6
3rd quintile 1.04 (0.54, 1.98) 0.9 1.48 (0.72, 3.03) 0.3 0.70 (0.37, 1.34) 0.3 2.84 (1.15, 7.05) 0.024
4th quintile 2.20 (1.09, 4.47) 0.038 1.75 (0.87, 3.51) 0.1 1.25 (0.64, 2.44) 0.5 1.82 (0.61, 5.45) 0.3
5th quintile (least poor) 2.19 (0.81, 5.93) 0.2 1.99 (0.71, 5.54) 0.2 2.21 (1.01, 4.82) 0.046 2.47 (0.93, 6.55) 0.070
Slept under a bed net the night
before the interview
1.60 (1.10, 2.34) 0.015 0.98 (0.59, 1.62) 0.9 1.23 (0.77, 1.96) 0.4 0.79 (0.50, 1.27) 0.3
Sought care within two days of
fever onset
1.01 (0.60, 1.72) 0.9 1.16 (0.63, 2.13) 0.6 1.61 (0.99, 2.61) 0.056 1.11 (0.59, 2.09) 0.8
Fever symptoms 3.38 (1.21, 9.47) 0.020 1.18 (0.56, 2.47) 0.7 1.65 (0.64, 4.25) 0.3 0.86 (0.47, 1.58) 0.6
Distance from home to outlet
within 2.5 km7
1.67 (1.05, 2.65) 0.031 0.76 (0.48, 1.20) 0.2 1.14 (0.68, 1.91) 0.6 1.09 (0.65, 1.82) 0.8
Time of day drug was obtained
Morning (ref) --- --- --- --- --- --- --- ---
Afternoon 1.11 (0.62, 2.01) 0.7 1.12 (0.52, 2.38) 0.8 0.55 (0.31, 0.97) 0.038 1.04 (0.57, 1.88) 0.9
Evening 0.81 (0.22, 3.04) 0.7 0.95 (0.44, 2.05) 0.9 0.10 (0.02, 47.6) 0.004 0.69 (0.31, 1.53) 0.4
Time between obtaining AL and
interview (hours)
60-67 (ref) --- --- --- --- --- --- --- ---
68-72 2.37 (0.87, 6.51) 0.093 2.80 (1.35, 5.82) 0.006 1.47 (0.44, 4.95) 0.5 1.55 (0.71, 3.36) 0.3
73-84 3.64 (1.31, 10.08) 0.013 2.73 (1.12, 6.63) 0.027 2.03 (0.56, 7.29) 0.3 2.94 (1.20, 7.20) 0.018
85 or more 5.59 (1.66, 18.79) 0.005 5.94 (2.70, 13.06) <0.001 2.72 (0.75, 9.84) 0.1 2.09 (0.85, 5.13) 0.1
Tested for malaria at outlet 1.30 (0.82, 2.04) 0.3 0.39 (0.17, 0.85) 0.018 1.47 (0.96, 2.26) 0.078 0.48 (0.24, 0.97) 0.041
Took first dose of AL at outlet 1.05 (0.71, 1.55) 0.8 1.34 (0.60, 3.01) 0.5 2.11 (1.46, 3.04) <0.001 1.33 (0.57, 3.13) 0.5
Recalled correct instructions
given by dispenser on the
number of pills per dose,
number of doses, and
number of days to take AL
4.04 (2.59, 6.31) <0.001 2.98 (2.03, 4.37) <0.001 6.09 (3.71, 10.02) <0.001 2.51 (1.41, 4.45) 0.002
Recalled that dispenser used
packaging as a visual aid to
explain how to take AL
1.33 (0.75, 2.36) 0.3 1.28 (0.62, 2.66) 0.5 1.85 (1.09, 3.11) 0.022 1.40 (0.73, 2.67) 0.3
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patterns of association between education and socioeco-
nomic status and either measure of adherence. Similar to
the previous analysis for the effect of sector, patients
obtaining AL in the afternoon or in the evening had lower
adjusted odds of timely completion than those obtaining
AL in the morning, although this was the case only in
public health facilities. In both public health facilities
and ADDOs, longer time between obtaining AL and
interview were again strongly associated with completed
treatment. However, there was no evidence of an associ-
ation with timely completion in public health facilities,
and in ADDOs only being interviewed 72–84 hours after
obtaining AL (not 68–72 hours or 85 hours or more) com-
pared to 60–67 hours was associated with timely comple-
tion. In addition, public health facility patients, but not
ADDO patients, sleeping under a bed net the night before
the interview, having experienced fever symptoms, and
living within 2.5 km of the outlet was associated with com-
pleted treatment, while seeking care within two days of
fever onset was associated with timely completion.
Factors related to care received at the outlet varied by
sector in their associations with both adherence measures
(Table 4). In the public sector, reporting being tested for
malaria at the outlet was not associated with completed
treatment (aOR = 1.30, 95% CI: 0.82, 2.04; p = 0.3), but
there was weak evidence of an association with timely
completion (aOR = 1.47, 95% CI: 0.96-2.29; p = 0.078).
Among ADDO patients, however, the adjusted odds of
completed treatment and timely completion were lower
for those who reported being tested compared to those
who did not report being tested (aOR = 0.39, 95% CI:
0.17-0.85; p = 0.018 and aOR = 0.48, 95% CI: 0.24, 0.97;
p = 0.041). There were no evident associations of taking
the first dose of AL at the outlet with completed treat-
ment in either sector or timely completion in ADDO
patients, but the adjusted odds of timely completion
were higher among health facility patients who took the
first dose of AL at the outlet (aOR: 2.11, 95% CI: 1.46,
3.04; p < 0.001). Recalling correct instructions given by the
dispenser on the AL regimen was strongly associated with
both measures of adherence in public health facility and
ADDO patients. In public health facilities, reporting that
the dispenser used the packaging as a visual aid to ex-
plain how to take AL was also associated with timely
completion (aOR = 1.77, 95% CI: 1.12, 2.80; p = 0.022).
In addition, the adjusted odds of timely completion
among ADDO patients who recalled being told to take
the second dose after eight hours were 1.77 times that
of their counterparts (95% CI: 1.12, 2.80; p = 0.015), but
recalling this advice was not associated with either meas-
ure of adherence in public health facility patients. Report-
ing being told to complete all doses of AL even if feeling
better was also not associated with either adherence meas-
ure, except for a lower adjusted odds of timely completion
in public health facility patients (aOR = 0.44, 95% CI: 0.28,
0.70; p = 0.001).
Discussion
This study indicates that patients seeking care for malaria
at public health facilities and ADDOs in southern Tanzania
have different characteristics, with those attending ADDOs
more likely to be older, more educated, wealthier, and seek-
ing treatment later in the day. Although similar propor-
tions of patients from both sectors completed treatment,
the proportion of patients taking each dose at the correct
time (timely completion) was lower in ADDO patients.
When controlling for patient characteristics, there was
some evidence that the adjusted odds of completed treat-
ment and timely completion were lower in ADDO pa-
tients compared to public health facility patients.
Completed treatment and timely completion among
patients from public health facilities were 75 and 46%,
respectively, comparable to other studies under real-life
conditions (i.e., not clinical trials) in the public sector,
which had found completed treatment verified by pill
count of 64-77% and timely completion verified by pill
count of 39-75% [10], including one study from Tanzania
[32]. Another study from the public sector in Tanzania
recently reported lower timely completion (14.9%) [35],
while two other studies using different definitions and
Table 4 Multivariate analyses of factors associated with adherence, by sector (Continued)
Reported being told to take the
second dose of AL eight hours
after the first dose
1.15 (0.74, 1.79) 0.5 1.28 (0.87, 1.89) 0.2 0.85 (0.52, 1.38) 0.5 1.77 (1.12, 2.80) 0.015
Reported being told to complete
all doses of AL even if feeling
better
0.96 (0.54, 1.71) 0.9 1.02 (0.61, 1.70) 0.9 0.44 (0.28, 0.70) 0.001 1.05 (0.73, 1.50) 0.8
1Patient completed all doses, verified by pill count when available. Data missing for 2 public health facility patients and 3 ADDO patients.
2Patient completed each dose at correct time with the correct number of pills per dose, verified by pill count when available. Data missing for 13 public health
facility patients and 10 ADDO patients.
3Standard errors adjusted for 37 clusters.
4Standard errors adjusted for 40 clusters.
5Age categories based on recommended age breakdown for AL blister packs in Tanzania.
6Wealth quintiles pooled for public health facilities and ADDOs using principal component analysis of sampled patients based on standard Demographic and
Health Survey variables.
7Based on GPS coordinates. Data missing from 30 public health facility patients and 52 ADDO patients.
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study designs found higher adherence (88.3 and 90%)
[33,34]. In ADDOs, completed treatment verified by pill
count was 70%, comparable to the 66% adherent by the
same definition in the study by Cohen et al. in the pri-
vate retail sector in Uganda [18].
Characteristics related to care received at the outlet
differed between sectors, with health facility patients
more likely to be tested for malaria at the outlet, be told
their diagnosis, take the first dose of AL at the outlet,
and receive advice on completing treatment even if feel-
ing better. However, there was no difference between
sectors in other advice patients reported receiving. It is
possible that advice provision in Mtwara region may
have been superior to that in other regions, as ADDOs
in Mtwara and Lindi regions received a one-day train-
ing, including ACT treatment, in 2011. In the sector-
specific models, some differences between sectors were
observed in the association of these characteristics with
completed treatment and timely completion, although
caution in interpretation is needed given the number of
comparisons made in the analyses. For example, in pub-
lic health facilities, obtaining a malaria test at the outlet
was not associated with completed treatment or timely
completion. However, in ADDOs, patients who reported
obtaining a malaria test appeared to be less adherent by
both measures. One explanation for this contrast might
be the status of mRDT roll out, which had occurred in
public health facilities in Mtwara several months prior
to the study, whereas ADDOs were not officially permit-
ted to use mRDTs, and only 50 patients (11%) reported
being tested (compared to 275 (54%) in public health fa-
cilities). The difference is not explained by reported test
results, as 96% of patients reporting a malaria test in
both sectors reported a positive result, though only 70% of
tested health facility patients and 35% of tested ADD0 pa-
tients had a positive study mRDT at interview.
At public health facilities, taking the first dose of AL
at the outlet was associated with timely completion, but
not completed treatment. In ADDOs, where less than 10%
of patients took the first dose at the outlet, there was no
evidence of an association with either measure of adher-
ence. Taking the first dose at the outlet might improve ad-
herence by providing a model for patients or caregivers on
how to take treatment, generating more communication
with patients, or improving their confidence to complete
the remaining doses at home. In addition, patients in both
sectors who recalled correct instructions on how to take
AL had much higher odds of completing treatment and
timely completion than patients who did not recall correct
instructions. This highlights the importance of clear in-
structions for achieving adherence [36]. A review of the
previous literature shows considerable variation in factors
associated with adherence to anti-malarials, but provision
of better information on how to take drugs has been an
important factor in more than one study [10]. Alterna-
tively, patients who are more conscientious about their
treatment may also be more likely to recall instructions.
Another factor that might affect adherence but was not
assessed reliably in this study is the attendance of the pa-
tient at the outlet, which is required to obtain treatment at
public health facilities but not at ADDOs. Patients who re-
ceived advice second-hand could be less likely to adhere.
However, this should not affect the comparison between
sectors, as whether or not the patient attended the outlet
might lie on the causal pathway between sector and adher-
ence, similar to the other variables related to care received
at the outlet. Other factors that were not assessed, related
to patient understanding of treatment or respect for dis-
pensers, might also be important in explaining adherence.
Timely completion was 30–35 percentage points lower
than completed treatment, even though timeliness of
doses was based on times of day rather than exact times.
While there is consensus that ACT will only be effective
if taken correctly, the importance for treatment effective-
ness of the recommended time intervals between doses is
less clear. In this study, only 46% of public health facility
patients and 35% of ADDO patients completed all doses
at the recommended intervals, and there was no associ-
ation between study mRDT positivity at interview (indi-
cating malaria infection at care seeking) and adherence.
While 50% of health facility patients and 28% of ADDO
patients were positive by study mRDT at interview, only
22 patients overall (approximately 2%) were positive by
reference blood smear, suggesting that most patients who
had been malaria positive at the time of care seeking may
have been treated effectively, even though only half of
these had completed all doses at the correct time. How-
ever, blood smears may not capture all submicroscopic
parasitaemia present at day 4, although these could lead to
subsequent treatment failure [37].
The dosing regimen for AL in national guidelines
states that doses should be taken at 0, 8, 24, 36, 48, and
60 hours, but for practical reasons a simpler regimen is
recommended, illustrated by pictograms on packaging,
which assume that patients obtain AL in the morning,
take the second dose later the same day, followed by the
remaining doses morning and evening for two more days
[22]. More patients from ADDOs than public health facil-
ities had obtained AL later in the day, as ADDOs had lon-
ger operating hours than public health facilities. Patients
who obtained AL in the evening in the analysis for the
effect of sector, and public health facility patients who
obtained AL in the afternoon or evening, had lower ad-
justed odds of timely completion than patients obtaining
AL in the morning. If eight hours after the first dose falls
in the middle of the night, patients may not wake up to
take the second dose, and they may be unsure when to
take the remaining doses. Modified recommendations and
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pictograms for patients obtaining AL in the evening may
be helpful in improving adherence, but this depends on
establishing a clearer basis for the importance of the tim-
ing of dose intervals.
This study has several limitations. Patients may have al-
tered their behaviour if they became aware of a potential
visit or study objectives. In an attempt to prevent this, in-
formation given to dispensers was limited, visits of study
research assistants to the outlets were minimized, and the
study was conducted in a large number of outlets, each
for a short period of time. The data presented here are
also based primarily on patient self-report, which is sus-
ceptible to recall bias and social desirability bias, if pa-
tients did not remember when each dose was taken or
provided the expected responses in order to avoid being
seen as negligent. In addition, patients’ consultations with
dispensers were intentionally not observed to avoid influ-
encing behaviour. Instead patients’ reports of care and ad-
vice received were analysed, though recall may not have
been accurate or advice of good quality. While dispensers’
characteristics and knowledge of advice to provide to pa-
tients were reported as part of the intervention study in
ADDOs [31], interviews of dispensers were not conducted
in health facilities, and it was therefore not possible to as-
sess the impact of these factors across the sectors. Simi-
larly, there may have been other important patient or
care-related factors that were not assessed.
This study was conducted in the context of AFMm-
subsidized ACT, and the median cost of AL in ADDOs
was low (approximately $0.04 per tablet, or $0.84 for an
adult equivalent treatment dose). In a setting without
AL subsidies, adherence could vary. One could argue that
lower adherence in ADDO patients could be a reason not
to continue a subsidy of ACT in these outlets. However,
the differences in adherence levels were not very large and
the reasons for the differences remain unclear. Moreover,
even if subsidized ACTs were not available in ADDOs (as
was previously the case) patients would likely continue
to seek care at these outlets, but obtain less effective
anti-malarials. Thus, improving care for malaria at both
ADDOs and public health facilities should be a priority.
Conclusion
Similar proportions of patients dispensed ACT from public
health facilities and ADDOs completed treatment, but the
proportion with timely completion was lower in ADDO
patients. Characteristics of patients obtaining ACT differed
between sectors. When controlling for patient characteris-
tics, there was some evidence that the adjusted odds of
completed treatment and timely completion for ADDO pa-
tients was lower than that for public health facility patients.
Further studies are necessary to understand and improve
the impact of patient care on adherence, including the role
of effective provision of advice.
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